# Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

> **NCT00006045** · PHASE3 · UNKNOWN · sponsor: **Facet Biotech**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** lintuzumab
- **DRUG:** cytarabine
- **DRUG:** etoposide
- **DRUG:** mitoxantrone hydrochloride

## Key facts

- **NCT ID:** NCT00006045
- **Lead sponsor:** Facet Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006045, "Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00006045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*